Evidence map›Paper›PMID 42324191›Full record

ArticleZhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery2026

[Orthopedic treatment strategy for hemophilic pseudotumor].

Jie Li, Yi'nan Liu, Pei Yang, Teng Lu, Xuan Cai, Haopeng Li, Ting Zhang

Abstract readEnglish Abstract
In one paragraph

Article in Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jie LiDepartment of Orthopedics, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an Shaanxi, 710004, P. R. China.
Yi'nan LiuDepartment of Orthopedics, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an Shaanxi, 710004, P. R. China.
Pei YangDepartment of Orthopedics, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an Shaanxi, 710004, P. R. China.
Teng LuDepartment of Orthopedics, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an Shaanxi, 710004, P. R. China.
Xuan CaiDepartment of Orthopedics, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an Shaanxi, 710004, P. R. China.
Haopeng LiDepartment of Orthopedics, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an Shaanxi, 710004, P. R. China.
Ting ZhangDepartment of Orthopedics, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an Shaanxi, 710004, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To summarize 10-year orthopedic experiences in the management of hemophilic pseudotumor and to discuss an individualized treatment strategy centered on surgery. Methods: The clinical data of 8 patients with hemophilic pseudotumor between June 2015 and May 2025 were retrospectively analyzed. All patients were male, aged 15-37 years, with a mean age of 27.3 years. Seven patients had hemophilia type A and 1 had hemophilia type B; all had severe hemophilia and no detectable inhibitor. The disease duration ranged from 2 months to 12 years, with a mean of 2.5 years. There were 7 soft-tissue pseudotumors and 1 osseous pseudotumor. Lesions involved the lower leg in 3 cases, the thigh in 1, the hip in 1, both the hip and thigh in 2, and both the knee and thigh in 1. Pseudotumor size ranged from 5 cm×5 cm×4 cm to 32 cm×19 cm×15 cm. Treatment modalities included conservative treatment in 1 case, pseudotumor excision in 5 cases, and transfemoral amputation in 2 cases. Perioperative factor replacement was administered according to hemophilia type and factor activity, followed by wound care, anti-infective treatment when needed, drainage management, and rehabilitation. Results: For 7 patients undergoing surgery, the operation time was 60-120 minutes (mean, 88.6 minutes), and the intraoperative blood loss was 150-700 mL (mean, 342.9 mL). Six patients received coagulation factor Ⅷ at doses of 25 400-40 000 U (mean, 32 600 U); 1 patient received coagulation factor Ⅸ at a dose of 35 000 U; the length of hospital stay was 15-30 days (mean, 22.1 days). All patients were followed up 2-10 years (mean, 3.9 years.). One patient developed a superficial wound infection, which resolved after sensitive antibiotics and dressing changes. One patient with a lower-leg soft-tissue pseudotumor healed after conservative treatment and had no recurrence. Among the 5 patients treated with pseudotumor excision, 1 patient with an osseous pseudotumor achieved satisfactory wound and bone healing after pseudotumor resection, allogeneic bone grafting, and internal fixation; 3 patients with soft-tissue pseudotumors had no recurrence during follow-up; and 1 patient with a giant hip soft-tissue pseudotumor developed recurrence with ulceration and massive bleeding at 2 years after surgery and eventually died after unsuccessful rescue at another hospital. The 2 patients who underwent amputation achieved wound healing and returned to daily life after prosthetic fitting and rehabilitation. Conclusion: Surgery remains the main treatment for hemophilic pseudotumors that fail conservative treatment or present with progressive enlargement, ulceration and infection, or compression of vital structures. Adequate perioperative factor coverage, precise preoperative imaging, complete excision whenever feasible, and meticulous elimination of dead space are essential to reduce complications and recurrence.

Indexed as

HematomaHemophilia AHemophilia BAdolescentAdultAmputation, SurgicalBlood Coagulation FactorsBone DiseasesFactor IXFactor VIIIHumansMaleRetrospective StudiesTreatment OutcomeYoung AdultBlood Coagulation FactorsFactor IXFactor VIIIcoagulation factor replacement therapyHemophilic pseudotumororthopedicsperioperative managementsurgical treatment

Identifiers

PMID42324191
PMCPMC13283928

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.